+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives

Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: physiopathogenetic and therapeutic perspectives

Seminars in Arthritis and Rheumatism 29(2): 65-81

To review the "core" systems interactions in rheumatoid arthritis (RA): neuroendocrine, immunologic, and microvascular, and to interpret an integrated physiopathogenesis of the disease, beginning at a preclinical phase of risk factors to the later stages of manifest clinical inflammation. Publications on stress reactions, serum hormonal levels, biological mediators of inflammation and vascular alterations in RA during its preclinical phase, course of active disease, including pregnancy, and hormonal therapy of active disease were retrieved. In addition, experimental reports on biological models of the disease were considered. Levels of adrenal and gonadal steroids (ie, glucocorticosteroids [GCS], dehydroepiandrosterone [DHEA], its sulfate [DHEAS], estradiol [E2], and testosterone [T]), as well as prolactin (PRL) and other hormones, biological mediators, vascular endothelial system (VES) interactions with hormones, and immunologic mediators of inflammation in RA, were reviewed and interpreted. Women with premenopausal onset of RA not previously treated with GCS had lower basal serum levels of adrenal androgens, that is, DHEA or DHEAS, both before and after onset of clinical disease, compared with controls. Risk factors, including hormonal, immunologic, and hereditary indicators, were found to be uniformly present many years before clinical onset in such younger women, as compared with a frequency of circa 15% in matched controls. Also, a history of heavy cigarette smoking significantly predicted the onset of RA in perimenopausal women, and in men, suggesting that vascular endothelial alterations predispose to the disease. In the same prospective study, 1 or more of 4 risk factors were present an average of 12 years before clinical onset of disease in 83% of male RA cases versus 26% in matched controls (ie, sensitivity of 83% and specificity of 74%). Early RA patients may have lower serum cortisol levels than normal controls, and less than expected for the degree of ongoing inflammation, as well as having upregulated PRL levels. Among persons genetically prone to RA, the "core" systems are hypothesized to become "remodeled" during a long preclinical phase as a result of chronic imbalances in their interactive homeostasis. This hypothesis needs to be critically assessed in further studies of such physiological precursors of disease as well as stressors in the development and course of RA. Optimal hormonal management of biological mediators of RA is also a priority challenge for disease control in the future. Evidence indicates that men and women who are susceptible to premenopausal onset of RA can each be identified long before their clinical onsets of disease, and that productive research in primary prevention is an achievable objective. Disease prevention objectives are central in the public health strategy of the National Arthritis Action Plan and of the US Public Health Service "Healthy People 2000" (and 2010 proposed). Success in such prevention goals can be expected to significantly reduce the enormous burden of this common disease, which affects all segments of the population.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 035378947

Download citation: RISBibTeXText

PMID: 10553979

DOI: 10.1016/s0049-0172(99)80039-0

Related references

Rheumatoid arthritis: neuroendocrine immune integrated physiopathogenetic perspectives and therapy. Rheumatic Diseases Clinics of North America 31(1): 131-60 X, 2005

Hormonal and immunologic risk factors for the development of rheumatoid arthritis: an integrative physiopathogenetic perspective. Rheumatic Diseases Clinics of North America 26(4): 775-803, 2000

Hormonal and pregnancy relationships to rheumatoid arthritis: convergent effects with immunologic and microvascular systems. Seminars in Arthritis and Rheumatism 25(1): 1-27, 1995

Interactions of autonomic nervous, neuroendocrine, and immune systems in rheumatoid arthritis. Rheumatic Diseases Clinics of North America 26(4): 841-857, 2000

The immunologic homunculus in rheumatoid arthritis. A new viewpoint of immunopathogenesis in rheumatoid arthritis and therapeutic consequences. Zeitschrift für Rheumatologie 60(1): 1-16, 2001

Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Expert Review of Vaccines 14(6): 891-908, 2015

Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. Neuroimmunomodulation 15(1): 19-28, 2008

Juvenile rheumatoid arthritis: therapeutic perspectives. Paediatric Drugs 4(5): 335-348, 2002

Polycystic ovarian syndrome and rheumatoid arthritis: possible physiopathogenetic clues to hormonal influences on chronic inflammation. Seminars in Arthritis and Rheumatism 33(2): 67-71, 2003

Effects of mirthful laughter on neuroendocrine and immune systems in patients with rheumatoid arthritis. Journal of Rheumatology 23(4): 793-794, 1996

Role of TNF-alpha and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives. Bulletin de l'Academie Nationale de Medecine 187(5): 935, 2003

Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clinical and Experimental Rheumatology 20(5 Suppl 27): S32-S34, 2004

Therapeutic Perspectives for Interferons and Plasmacytoid Dendritic Cells in Rheumatoid Arthritis. Trends in Molecular Medicine 24(4): 338-347, 2018

Use of synthetic antimalarial drugs and other agents for rheumatoid arthritis: historic and therapeutic perspectives. American Journal of Medicine 75(1a): 1-4, 1983

Rheumatoid arthritis-associated interstitial lung disease : new genetic data and therapeutic perspectives. Revue Medicale Suisse 15(641): 536-541, 2019